Skip to main content
HairCited

Minoxidil für Alopecia Areata

A

Basierend auf 48 Studien (2 meta-analyses, 1 RCT) mit 21,842 Teilnehmern insgesamt. 37/48 Studien zeigen positive Effekte.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dalopecia\u002Dareata'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Fazit

Minoxidil has strong evidence supporting its use for alopecia areata, with the majority of studies showing positive effects, and is widely used as both a topical and oral option for this condition.

  • 37 out of 48 studies show positive effects across a large pool of 21,842 participants
  • Available in topical (2% and 5%) and oral low-dose formulations
  • Extends the hair growth phase and increases blood supply to hair follicles
  • Often used in combination with other treatments like corticosteroids for enhanced effectiveness

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: women with androgenetic alopecia (female pattern hair loss)

Case Reports n=1
Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case …
Dose: None vs.: None Outcome: hair regrowth in severe alopecia areata Wirkung: None None

Population: patient with severe alopecia areata with suboptimal response to tofacitinib

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs.: Placebo Wirkung: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: None

review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri vs.: Placebo Wirkung: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None
retrospective cohort study n=321
Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.
Dose: Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi vs.: Placebo Wirkung: 91.3% received definitive remote diagnosis; only 8.7% required in-person follow-up. AA most common ( None

Key Statistics

122

Studien

27416

Teilnehmer

Positive

A

Bewertung

Referenced Papers

Dermatologic clinics 2025 5 Zitierungen
Pediatric dermatology 2025 5 Zitierungen
Journal of the … 2025 2 Zitierungen
International journal of … 2025 1 Zitierungen
Journal of clinical … 2025 1 Zitierungen
Archives of dermatological … 2025
International journal of … 2024 39 Zitierungen
American family physician 2024 8 Zitierungen
Skin health and … 2024 7 Zitierungen
Journal of the … 2024 7 Zitierungen
The Journal of … 2024 2 Zitierungen
Archives of dermatological … 2023 16 Zitierungen
The Cochrane database … 2023 2 Zitierungen
The Journal of … 2022 170 Zitierungen
Journal of the … 2022 90 Zitierungen
Dermatology and therapy 2022 43 Zitierungen
Skin appendage disorders 2022 7 Zitierungen
JAAD case reports 2022 2 Zitierungen
The American Journal … 2022 2 Zitierungen
Clinical reviews in … 2021 304 Zitierungen
Journal of dermatological … 2021 51 Zitierungen
Dermatologic therapy 2021 30 Zitierungen
American journal of … 2020 127 Zitierungen
International journal of … 2020 58 Zitierungen
The journal of … 2020 3 Zitierungen
The Australasian journal … 2019 152 Zitierungen
American journal of … 2019 84 Zitierungen
Journal of the … 2019 50 Zitierungen
Expert opinion on … 2019 34 Zitierungen
Klinicka onkologie : … 2019 11 Zitierungen
Journal of the … 2018 114 Zitierungen
Dermatology online journal 2018
American family physician 2017 141 Zitierungen
American journal of … 2017 32 Zitierungen
Actas dermo-sifiliograficas 2017 17 Zitierungen
Deutsches Arzteblatt international 2016 99 Zitierungen
Current problems in … 2015 322 Zitierungen
The Medical clinics … 2015 66 Zitierungen
Canadian family physician … 2015 31 Zitierungen
The journal of … 2015 25 Zitierungen
Current problems in … 2015 18 Zitierungen
Der Internist 2015
Lasers in surgery … 2014 243 Zitierungen
American journal of … 2014 82 Zitierungen
Expert opinion on … 2014 57 Zitierungen
Giornale italiano di … 2014 18 Zitierungen
Giornale italiano di … 2014
International journal of … 2013 61 Zitierungen
Recent patents on … 2011 6 Zitierungen
Seminars in cutaneous … 2009 85 Zitierungen
American family physician 2009
The Cochrane database … 2008 222 Zitierungen
Current opinion in … 2008 31 Zitierungen
International journal of … 2007 185 Zitierungen
Alopecia areata. Case Report
Dermatology nursing 2007
The Australasian journal … 2006
Journal of the … 2005 44 Zitierungen
Cleveland Clinic journal … 2005
Praxis 2003 28 Zitierungen
American family physician 2003 2 Zitierungen
American family physician 2003
American journal of … 2000 28 Zitierungen
International journal of … 1999 16 Zitierungen
Dermatologic clinics 1998 121 Zitierungen
American family physician 1990
Dermatologic clinics 1987
Journal of the … 1984 122 Zitierungen
Journal of the … 1984
Archives of dermatology 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

topical:
2-5% solution, twice daily

Obergrenze: 5% topical solution

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Neutral --
None -- Positive 1
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Mixed --
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri -- Positive --
Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi -- Positive 321
None -- Mixed --
None -- Mixed 1

Beste Einnahmezeit: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

Bekannte Wechselwirkungen

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

Tolerierbare Höchstaufnahmemenge: 5% topical solution

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Minoxidil help with Alopecia Areata?
Based on 122 studies with 27,416 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Alopecia Areata management. Our evidence grade is A (Strong Evidence).
How much Minoxidil should I take for Alopecia Areata?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Minoxidil?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Minoxidil and Alopecia Areata?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 122 peer-reviewed studies with 27,416 total participants. The overall direction of effect is positive.

Related Evidence

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.